Therefore, analysis of the association between BARD1 truncating mutations and prostate cancer risk in other populations would require sequencing of the entire gene in large case–control study (given the ≤0.05% mutation frequency in other ethnic groups, at least approximately 15,000 cases and 30,000 controls should be screened, to have comparable power to our current study). The gene discussed is BARD1; the disease is Familial prostate cancer.